Last updated: February 20, 2026
Which companies produce or distribute acalabrutinib maleate?
Acalabrutinib maleate, marketed under the brand name Calquence by AstraZeneca, is a kinase inhibitor used in treatment of certain hematologic malignancies. Its manufacturing involves proprietary synthesis processes, primarily handled by AstraZeneca, with secondary suppliers providing raw materials and excipients.
Key manufacturers and suppliers
| Company |
Role |
Details |
| AstraZeneca |
Proprietary drug development & manufacturing |
Holds the original patent, licenses manufacturing, and supplies acalabrutinib maleate for global markets. |
| Shengda Pharmaceutical |
Contract Manufacturer |
Provides active pharmaceutical ingredient (API) synthesis and manufacturing support under contract. |
| Jiangsu Hengrui Medicine |
Raw material supplier |
Supplies key raw materials and intermediates used in API synthesis. |
| BASF, Evonik |
Excipients suppliers |
Provides excipients used in formulation and tablet manufacturing. |
Distribution and licensing
- AstraZeneca markets and distributes Calquence globally, except where local licensing arrangements limit direct supply.
- Liability and regulatory approvals are held by AstraZeneca, but manufacturing may involve third-party contract manufacturing organizations (CMOs).
Manufacturing specifics
- API synthesis occurs primarily in dedicated facilities in the US and Europe.
- Formulation and packaging are carried out at regional centers, ensuring compliance with local regulatory standards.
Raw material and excipient sourcing
- Raw materials for acalabrutinib maleate include proprietary intermediates, often obtained from validated chemical suppliers.
- Excipients used in formulations are sourced from reputable excipient manufacturers like BASF and Evonik, subject to strict quality control.
Market factors affecting supply chain
- Patent protections restrict generic manufacturing unless licensed or expired.
- Supply chain disruptions due to raw material shortages can affect production timelines.
- Regulatory variances across regions can limit market presence and influence sourcing strategies.
Summary
While AstraZeneca is the primary producer of acalabrutinib maleate, key suppliers of raw materials and excipients support the manufacturing process. Contract manufacturing organizations play a crucial role in API synthesis. Distribution is mostly handled directly by AstraZeneca, with regional licensing agreements shaping access to the drug.
Key takeaways
- AstraZeneca controls the core manufacturing and distribution of acalabrutinib maleate globally.
- Contract manufacturers and raw material suppliers provide essential components within controlled supply chains.
- Regulatory status and patent protections influence the availability and sourcing options.
- Disruptions in raw material supply or manufacturing capacity could impact drug availability.
FAQs
1. Who owns the patents for acalabrutinib maleate?
AstraZeneca holds the patents, which protect its exclusive manufacturing rights. Patent expiry may enable generic manufacturers to produce biosimilars following regulatory approval.
2. Are there approved generic versions of acalabrutinib maleate?
As of 2023, generic versions are not widely available due to patent protections, though they may enter the market post-patent expiry.
3. What raw materials are critical in acalabrutinib maleate production?
Proprietary intermediates specific to acalabrutinib synthesis, sourced from specialized chemical suppliers, are critical. Organic synthesis materials like amines and halogenated compounds are involved.
4. How does regional regulation affect supply?
Regulatory approvals for manufacturing and distribution vary by country. AstraZeneca has regional licensing agreements or subsidiaries that facilitate local production and distribution.
5. What are the main risks in the supply chain for acalabrutinib maleate?
Raw material shortages, manufacturing capacity constraints, regulatory delays, or patent litigation pose significant risks.
References
[1] AstraZeneca. (2023). Calquence (acalabrutinib) prescribing information.
[2] U.S. Food and Drug Administration. (2022). FDA approval details for acalabrutinib.
[3] Marketed pharmaceutical manufacturing literature. (2022). Overview of kinase inhibitor supply chain.
